Edition:
India

Shilpa Medicare Gets USFDA Approval For Its ANDA, Gemcitabine For Injection USP


Monday, 25 Feb 2019 

Feb 25 (Reuters) - Shilpa Medicare Ltd ::SAYS GOT USFDA APPROVAL FOR ITS ANDA, GEMCITABINE FOR INJECTION USP, 200 MG/VIAL AND 1 G/VIAL.SHILPA MEDICARE-DRUG IS GENERIC EQUIVALENT OF DRUG USED IN TREATMENT OF OVARIAN CANCER, BREAST CANCER, NON-SMALL CELL LUNG CANCER & PANCREATIC CANCER. 

Latest Developments forShilpa Medicare Ltd

Company Quote

304.15
6.05 +2.03%
21 Nov 2019